Bringing Your STX209 Data Home
The National Fragile X Foundation, with the help of several professionals, has secured an agreement to obtain STX209 trial participant data through a reconsent process.
We need a total of 150 participants. If your family was involved in the STX209 trials, please help expand your past effort — it will only take a few minutes. The original data has been unavailable for many years, and you can help us bring it back to the community, via the NFXF Data Repository↗, by providing consent to bring the data home!
Progress
^ 0%
^ 50%
100% ^
How Do I Participate?
You can start here with two easy steps.
1. Check your eligibility
You (or someone you represent) must have previously participated in the STX209 trials.
If the participant is a minor, a parent, caregiver, or legally authorized representative must be available to provide consent.
- Watch and listen to a quick video (6:35) featuring Dr. Berry-Kravis, Hilary Rosselot (NFXF director of research facilitation), and Missy Zolecki (NFXF director of community engagement), who discuss this exciting new project and what it means for all of us
- Read more about the STX209 trials
- Learn more about how the data will be used
- Check out the frequently asked questions
- Learn more about the NFXF Data Repository
- And, if you need additional help, Hilary walks you through the form process in our STX209 Reconsent How-To video — or contact us directly!
About the STX209 Trials
The STX209 trials were medication trials studying arbaclofen in Fragile X syndrome. Many families participated in these studies over multiple years. In the two Phase III trials, arbaclofen did not meet the primary outcome of improved social avoidance in FXS in either study. This resulted in the STX209 program shutting down. The data from these trials stayed with the sponsor organization for safe keeping.
For more information on these trials:
- Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial
- Arbaclofen in fragile X syndrome: results of phase 3 trials
Families and professionals expressed their disappointment in the STX209 program ending. There was hope that the data would be made available for future research and possibly to even help with future trials to study arbaclofen in FXS for a drug approval. Until now, this has not been an option.
We have been able to work with the organization storing the data to move forward with obtaining your data, but we need your help!
WATCH: STX209 Consent Discussion
WITH:
Hilary Rosselot, NFXF Executive Director, Research Facilitation Lead
Missy Zolecki, NFXF Director, Community Empowerment
Dr. Elizabeth Berry-Kravis
Here we’ve provided a quick video (6:35) featuring Dr. Berry-Kravis, Hilary Rosselot (NFXF director of research facilitation), and Missy Zolecki (NFXF director of community engagement), who discuss this exciting new project and what it means for all of us.
How We Want to Use the Data
We want this data to live in the NFXF Data Repository for future research. Participants, their families, and professionals spent a lot of time and energy on these trials. The data could be useful for different types of future research, including new arbaclofen or other medication trials, and we believe NFXF is best equipped to house this data. Your past data could help advance other scientific achievements in Fragile X.
Why NFXF?
NFXF is a patient advocacy group, and we are not going anywhere! No trial data should be lost after the trial concludes — it should reside in the community for researchers to utilize for scientific achievement. The NFXF Data Repository is the most appropriate place for your data to live. We can make the data available to the larger community for de-identified, secure research. Including the data as a part of the NFXF Data Repository is the start of what we hope will happen with all future trial data.
NFXF is committed to advocating for this data transfer approach in all future clinical trials so no data is ever lost.
This means that after an initial research project has concluded, any leftover, de-identified data should be rolled over into the NFXF Data Repository to be made available for future research. This could alleviate burden on the FX community, as researchers could start their research using the NFXF Data Repository. Bringing the STX209 data home is a step toward a brighter future for Fragile X!
Prior STX209 Trial Participants
We know it takes time and dedication to participate in a trial. Science cannot move forward without your participation. The original data has been unavailable for many years, help us bring it back to our community by providing consent to bring the data home!
Who Can Participate
Only those individuals who had previously participated in the STX209 trials. The participant and/or a parent, caregiver, or legally authorized representative must be available to provide consent.
What’s Involved
Providing consent for data transfer is completed via an online form (the secure database is provided by Rush University), which asks a few questions about yourself and which study site you went to when you participated in the STX209 studies. This should take no more than 15 minutes. If needed, you’ll be able to save your work and come back to it if you’re not able to complete it one sitting.
WATCH
How to Fill Out the STX209 Reconsent Form
What Happens Next
Once completed, your past STX209 data will be transferred to the NFXF Data Repository, where the now de-identified clinical and biological data may be queried by other researchers conducting projects in Fragile X.
Registrants may also be contacted about research studies they may be eligible to participate in, including future treatment studies.
If any of your questions have not been answered here, we have additional FAQs below. Still have questions? Contact us, and we’ll do everything we can to assist you and your family with the STX209 reconsent process.
Frequently Asked Questions
When you consented to participate in the STX209 studies, you consented to your data being used specifically for that purpose. When you provide your consent, you are informed of the ways your data may be used. The STX209 studies are over and you did not initially provide consent for your data to be used for future research. We take your consent very seriously. For your data to be transferred, we need you to provide your consent for future research to be done on your de-identified data.
No personal data is shared with anyone outside this team. Researchers who want to query the NFXF Data Repository, where your data will be stored, must first submit an application that will be reviewed and approved by the NFXF Data Repository Governance Committee. This committee will include expert researchers, clinicians, and Fragile X advocates. After approval, your de-identified clinical and biological data may be used in the research project.
Yes, unless you consent to being contacted directly by researchers. As a participant, you will be able to indicate if you are interested in being contacted about future research. This is optional, you can participate in this project no matter what you choose.
If you consent to being contacted about future research opportunities, the study team may share information about new research by email or mail with you. It will be up to you whether to move forward with that research project.
No. The choice to participate in this project is completely voluntary and will not affect your medical care in any way.
Thanks! We will communicate your permission with the sponsor organization who is holding your data. This may take some time, but we will keep everyone updated through regular communications through NFXF channels.
Questions?
If you have questions about anything research-related, we’d love to hear from you! You can reach out to Hilary Rosselot directly, or submit your question or comment through our contact form below.
Anna De Sonia, Director of Research Facilitation
anna@fragilex.org